LECs in the tumor-draining LN can cross-present tumor antigens on MHC-I to induce tolerance of tumor-specific CD8+ T cells similar to the ability of steady-state LECs to present endogenous self-antigens on MHC-I to suppress autoreactive CD8+ T cells [23]. This evidence concerns the gene CD8A and neoplasm.